| Nome |
# |
|
Entinostat for the treatment of breast cancer, file dfa8b99f-34e8-748b-e053-3a05fe0a3a96
|
839
|
|
Impact of baseline and on-treatment glycemia on everolimus-exemestane efficacy in patients with hormone receptor-positive advanced breast cancer (EVERMET), file dfa8b9a7-17d2-748b-e053-3a05fe0a3a96
|
413
|
|
Practical classification of triple-negative breast cancer: intratumoral heterogeneity, mechanisms of drug resistance, and novel therapies, file dfa8b9a6-3470-748b-e053-3a05fe0a3a96
|
389
|
|
Benefit of adjuvant chemotherapy in patients with special histology subtypes of triple-negative breast cancer : a systematic review, file dfa8b9a7-0a7a-748b-e053-3a05fe0a3a96
|
253
|
|
Expression of tumor-associated antigens in breast cancer subtypes, file dfa8b9a0-784e-748b-e053-3a05fe0a3a96
|
228
|
|
Repurposing anticancer drugs for the management of COVID-19, file dfa8b9a5-e66e-748b-e053-3a05fe0a3a96
|
156
|
|
Mismatch Repair Deficiency as a Predictive Biomarker for Immunotherapy Efficacy, file dfa8b99b-1c98-748b-e053-3a05fe0a3a96
|
129
|
|
The experience on coronavirus disease 2019 and cancer from an oncology hub institution in Milan, Lombardy Region, file dfa8b9a6-01f8-748b-e053-3a05fe0a3a96
|
94
|
|
How to Best Exploit Immunotherapeutics in Advanced Gastric Cancer : Between Biomarkers and Novel Cell-Based Approaches, file dfa8b9a6-f92b-748b-e053-3a05fe0a3a96
|
94
|
|
Biases in study design, implementation, and data analysis that distort the appraisal of clinical benefit and ESMO-Magnitude of Clinical Benefit Scale (ESMO-MCBS) scoring, file dfa8b9a6-885e-748b-e053-3a05fe0a3a96
|
90
|
|
Assessing Population Diversity in Phase III Trials of Cancer Drugs Supporting FDA Approval in Solid Tumors, file dfa8b9a7-7a65-748b-e053-3a05fe0a3a96
|
88
|
|
Master protocols in immuno-oncology : Do novel drugs deserve novel designs?, file dfa8b9a5-ca70-748b-e053-3a05fe0a3a96
|
76
|
|
Evolving treatment landscape of immunotherapy in breast cancer: current issues and future perspectives, file a277b3d5-ef2c-46db-ad74-df4d3718840c
|
75
|
|
ESMO Management and treatment adapted recommendations in the COVID-19 era: Breast Cancer, file dfa8b9a5-d6a9-748b-e053-3a05fe0a3a96
|
68
|
|
European Society for Medical Oncology (ESMO) 2018 Congress Twitter analysis : From ethics to results through the understanding of communication and interaction flows, file dfa8b9a5-e046-748b-e053-3a05fe0a3a96
|
61
|
|
Management of Cardiac Toxicity Induced by Chemotherapy, file dfa8b9a5-e35d-748b-e053-3a05fe0a3a96
|
54
|
|
Conducting phase 1 cancer clinical trials during the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)–related disease pandemic, file dfa8b9a5-fed9-748b-e053-3a05fe0a3a96
|
52
|
|
COVID-19 vaccines in patients with cancer, file dfa8b9a7-46d1-748b-e053-3a05fe0a3a96
|
45
|
|
Baseline Tumor Size as Prognostic Index in Patients With Advanced Solid Tumors Receiving Experimental Targeted Agents, file 3313c5a7-8117-463e-ac51-1492ce112453
|
40
|
|
Management of patients with HER2-positive metastatic breast cancer after trastuzumab deruxtecan failure, file 10d7fa00-e17f-4879-b3ab-92b7e2ad7a7f
|
29
|
|
Distribution of the workforce involved in cancer care: a systematic review of the literature, file dfa8b9a9-b877-748b-e053-3a05fe0a3a96
|
29
|
|
Safety of covid-19 mrna vaccines in patients with cancer enrolled in early-phase clinical trials, file dfa8b9a9-e0ee-748b-e053-3a05fe0a3a96
|
29
|
|
Impact of baseline and on-treatment glycemia on everolimus-exemestane efficacy in patients with hormone receptor-positive advanced breast cancer (EVERMET), file dfa8b9a6-fca6-748b-e053-3a05fe0a3a96
|
23
|
|
WHO model list of essential in vitro diagnostics: strengthening diagnostics capacity to transform health care for all, file 2aa638ee-ca0c-45dc-a580-e17f5fdbbc3e
|
15
|
|
Accelerating progress in early triple-negative breast cancer: A viewpoint on antibody-drug conjugates, back from St Gallen breast cancer conference 2021, file 1302eac9-9965-45ec-bebc-4759ebaba6f5
|
9
|
|
Strategies to modulate the immune system in breast cancer : checkpoint inhibitors and beyond, file dfa8b99b-0fab-748b-e053-3a05fe0a3a96
|
7
|
|
Clinical efficacy of ribociclib as a first-line therapy for HR-positive, advanced breast cancer, file dfa8b99b-7766-748b-e053-3a05fe0a3a96
|
7
|
|
Genomic analysis of circulating tumor DNA to predict endocrine resistance and clonal evolution in patients with prostate cancer : clinical perspectives and research opportunities, file dfa8b99b-5762-748b-e053-3a05fe0a3a96
|
6
|
|
The global landscape of drug development for kidney cancer, file dfa8b9a5-da93-748b-e053-3a05fe0a3a96
|
5
|
|
Fed or fasted state for oral therapies in breast cancer treatment? A comprehensive review of clinical practice recommendations, file dfa8b9a7-dbef-748b-e053-3a05fe0a3a96
|
5
|
|
Grading of recommendations, assessment, development and evaluations concept 7: issues and insights linking guideline recommendations to trustworthy essential medicine lists, file e37b9d2b-7bc0-4015-9f43-4acbaf7fe0a0
|
5
|
|
The Emerging Role of "Liquid Biopsies," Circulating Tumor Cells, and Circulating Cell-Free Tumor DNA in Lung Cancer Diagnosis and Identification of Resistance Mutations, file dfa8b99a-c3dd-748b-e053-3a05fe0a3a96
|
3
|
|
Prognostic and predictive value of tumor infiltrating lymphocytes in early breast cancer, file dfa8b99b-1d68-748b-e053-3a05fe0a3a96
|
3
|
|
Complexity of genome sequencing and reporting: Next generation sequencing (NGS) technologies and implementation of precision medicine in real life, file dfa8b99d-3bcc-748b-e053-3a05fe0a3a96
|
3
|
|
Targeting the microenvironment in solid tumors, file dfa8b99d-3c40-748b-e053-3a05fe0a3a96
|
3
|
|
Managing cancer patients during the COVID-19 pandemic: an ESMO multidisciplinary expert consensus, file dfa8b9a5-e433-748b-e053-3a05fe0a3a96
|
3
|
|
The global landscape of treatment standards for breast cancer, file dfa8b9a6-3399-748b-e053-3a05fe0a3a96
|
3
|
|
Adjuvant treatment of early male breast cancer, file dfa8b9a6-70cc-748b-e053-3a05fe0a3a96
|
3
|
|
Baseline tumor size as prognostic index in patients with cancer receiving experimental targeted agents, file 7274a766-ca39-47ea-b580-0b41c0acc128
|
2
|
|
The evolving landscape of ‘next-generation’ immune checkpoint inhibitors: A review, file dfa8b99f-60f6-748b-e053-3a05fe0a3a96
|
2
|
|
Evaluating triptorelin as a treatment option for breast cancer, file dfa8b9a5-d55f-748b-e053-3a05fe0a3a96
|
2
|
|
How to treat lobular cancer in the adjuvant setting?, file dfa8b9a6-104c-748b-e053-3a05fe0a3a96
|
2
|
|
Benefit of adjuvant chemotherapy in patients with lobular breast cancer : A systematic review of the literature and metanalysis, file dfa8b9a6-8924-748b-e053-3a05fe0a3a96
|
2
|
|
The Emergence of Immune-checkpoint Inhibitors in Colorectal Cancer Therapy, file dfa8b9a7-1b03-748b-e053-3a05fe0a3a96
|
2
|
|
A conceptual framework for cautious escalation of anticancer treatment: How to optimize overall benefit and obviate the need for de-escalation trials, file 205ba3b7-5cf4-4c7b-b1dc-d2484f2f99c9
|
1
|
|
Primary malignant phyllodes tumors of the breast: A retrospective analysis from a referral center, file 62a41da8-b553-4895-9a15-95956c44b53f
|
1
|
|
Impact of Prior Authorization on Patient Access to Cancer Care, file c78e4ad0-7684-4494-a2d5-c151f5b691c0
|
1
|
|
Liver toxicity in the era of immune checkpoint inhibitors: A practical approach, file dfa8b99d-1c3e-748b-e053-3a05fe0a3a96
|
1
|
|
Pharmacological management of male breast cancer, file dfa8b9a3-1f9d-748b-e053-3a05fe0a3a96
|
1
|
|
How can biosimilars change the trajectory of breast cancer therapy?, file dfa8b9a5-e744-748b-e053-3a05fe0a3a96
|
1
|
|
The evolving paradigm of biomarker actionability: Histology-agnosticism as a spectrum, rather than a binary quality, file dfa8b9a6-67c3-748b-e053-3a05fe0a3a96
|
1
|
|
Immunotherapy addition to neoadjuvant chemotherapy for early triple negative breast cancer: A systematic review and meta-analysis of randomized clinical trials, file dfa8b9a6-68b5-748b-e053-3a05fe0a3a96
|
1
|
|
Benefit of adjuvant chemotherapy in patients with special histology subtypes of triple-negative breast cancer : a systematic review, file dfa8b9a6-ee6c-748b-e053-3a05fe0a3a96
|
1
|
|
Mastering the Use of Novel Anti-HER2 Treatment Options, file dfa8b9a6-f87e-748b-e053-3a05fe0a3a96
|
1
|
|
First line treatment of BRAF mutated advanced melanoma: Does one size fit all?, file dfa8b9a7-83d9-748b-e053-3a05fe0a3a96
|
1
|
|
Assessing Population Diversity in Phase III Trials of Cancer Drugs Supporting FDA Approval in Solid Tumors, file dfa8b9a7-fba0-748b-e053-3a05fe0a3a96
|
1
|
|
Evolution of low HER2 expression between early and advanced-stage breast cancer, file dfa8b9a9-77e9-748b-e053-3a05fe0a3a96
|
1
|
|
Global challenges and policy solutions in breast cancer control, file dfa8b9a9-77eb-748b-e053-3a05fe0a3a96
|
1
|
|
National health system characteristics, breast cancer stage at diagnosis, and breast cancer mortality: a population-based analysis, file dfa8b9a9-8a46-748b-e053-3a05fe0a3a96
|
1
|
| Totale |
3.461 |